Sitaxsentan sodium. Endothelin ET(A) antagonist treatment of heart failure treatment of pulmonary hypertension

Drugs of the Future

Volumn 25, Issue 2, 2000, Pages 159-164

  Graul, A ^a   Leeson, P A ^a   Castaner J ^a  

^a PROUS SCIENCE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

2 BUTYL 7 [2 (2 CARBOXYPROPYL ) 4 METHOXYPHENYL] 5 (3,4 METHYLENEDIOXYPHENYL)CYCLOPENTENO[1,2 B]PYRIDINE; 27 O 3 [2 (3 CARBOXYACRYLOYLAMINO) 5 HYDROXYPHENYL]ACRYLOYLOXY MYRICERONE; 4 (4 METHOXYPHENYL) 2 (3,4 METHYLENEDIOXYPHENYL) 4 OXO 3 (3,4,5 TRIMETHOXYBENZYL) 2 BUTENOIC ACID; ATRASENTAN; BMS 193884; BOSENTAN; CLAZOSENTAN; DARUSENTAN; ENDOTHELIN A RECEPTOR ANTAGONIST; ENDOTHELIN B RECEPTOR ANTAGONIST; ENRASENTAN; SARAFOTOXIN S6C; SITAXENTAN SODIUM; SITAXSENTAN; TAK 044; TEZOSENTAN; UNCLASSIFIED DRUG;

BRAIN ISCHEMIA; CLINICAL TRIAL; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDICATION; DRUG MECHANISM; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TOLERABILITY; HEADACHE; HEART FAILURE; HUMAN; HYPEREMIA; HYPERTHERMIA; KIDNEY FAILURE; NAUSEA; NONHUMAN; PULMONARY HYPERTENSION; REVIEW;

EID: 0034028141     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2000.025.02.567157     Document Type: Review

References (33)

1. Chan, M.F., RaJu, B.G., Kois, A., Verner, E.J., Wu, C., Castillo, R,S., Yalamoori, V., Balaji, V.N. (Texas Biotechnology Corp.). Thienyl-, furyl-, pyrrolyl- and biphenylsulfonamides and derivs. thereof that modulate the activity of endothelin. EP 819125, JP 1999507015, WO 9631492.
2. Wu, C., Blok, N., Kogan, T., Keller, K., Woodard, P. (Texas Biotechnology Corp.). Sulfonamides for treatment of endothelin-mediated disorders. US 5783705, WO 9849162.
3. Wu, C., Chan, M.F., Stavros, F., Raju, B., Okun, I., Mong, S., Keller, K.M., Brock, T., Kogan, T.P., Dixon, R.A.F. Discovery of TBC11251, a potent, long acting, orally active endothelin receptor-A selective antagonist, J Med Chem 1997, 40: 1690-7.
4. Inoue, A., Yanagisawa, M., Kimura, S., Kasuya, Y., Miyauchi, T., Goto. K., Masaki, T. The human endothelin family: Three structurally and pharmacologically distinct isopeptides predicted by three separate genes. Proc Nail Acad Sci USA 1989, 86: 2863-7.
5. Prous, J.R. Heart failure therapy. In: The Year's Drug News -Therapeutic Targets, 1995 Edition, Prous Science, Barcelona, 1995. 235-45.
6. A selective endothelin antagonists. 211th ACS Natl Meet (March 24-28, New Orleans) 1996, Abst MEDI 148.
7. Chen, S.J., Brock, T., Stavros, F., Okun, I., Wu, C., Chan, F., Mong, S., Dixon, R.A.F., Oparil, S., Chen, V.F TBC11251, a highly selective endothelin-A receptor antagonist, prevents and reverses acute hypoxia-induced pulmonary hypertension in the rat. FASEB J 1996, 10(3): Abst 601.
8. Wanebo, J.E., Arthur, A.S., Louis, H.G., West, K., Kassell, N.R, Lee, K.S., Helm, G.A. Systemic administration of the endothelin-A receptor antagonist TBC 11251 attenuates cerebral vasospasm after experimental subarachnoid hemorrhage: Dose study and review of endothelin-based therapies in the literature on cerebral vasospasm. Neurosurgery 1998, 43:1409-17.
9. Pasceri, V., Wu, H., Brock, T., Yeh, E.T.H., Willerson, J.T. Inhibition of monocyte/macrophage homing to atherosclerotic plaque by treatment with endothelin receptor-A antagonist. Circulation 1999, 100(18, Suppl. 1): Abst 66.
10. A endothelin receptor antagonist, in spontaneously hypertensive hamsters. 6th Int Conf Endothelin (Oct 10-13, Montreal) 1999, Abst O45.
11. A receptor blockade reduces pulmonary vascular resistance in patients with chronic heart failure. Circulation 1998, 98(17, Suppl.): Abst 3044.
12. Successful results contribute to early termination of phase IIa study of TBC-11251. DailyDrugNews.com (Daily Essentials) February 13, 1998.
13. Texas Biotechnology reports additional positive phase IIa trial results for TBC-11251. DailyDrugNews.com (Daily Essentials) July 29, 1998.
14. Texas Biotechnology announces new preclinical, clinical data and future plans for sitaxsentan. DailyDrugNews.com (Daily Essentials) Oct 19, 1999.
15. Financial results and R&D highlights at Texas Biotechnology. DailyDrugNews.com (Daily Essentials) Nov 24, 1999.
16. TBC-11251 development status. Texas Biotechnology Company Communication Nov 3, 1999.
17. A-selective receptor antagonist. J Pharmacol Exp Ther 1996, 276: 473-81.
18. A selective endothelin receptor antagonists. 1. Discovery of A-127722. J Med Chem 1996, 39: 1039-48.
19. Hoshino, T., Yamauchi, R., Kikkawa, K., Yabana, H., Murata, S. Pharmacological profile of T-0201, a highly potent and orally active endothelin receptor antagonist. J Pharmacol Exp Ther 1998, 286: 643-9.
20. A antagonist, TA-0201 and related compounds. 216th ACS Natl Meet (Aug 23-27. Boston) 1998, Abst MEDI 057.
21. Wu-Wong, J.R., Dixon, D.B., Chiou, W.J., Opgenorth, T.J. Endothelin receptor antagonists: Effect of serum albumin on potency and comparison of pharmacological characteristics. J Pharmacol Exp Ther 1997, 281: 791-8.
22. B endothelin receptor antagonist. J Pharmacol Exp Ther 1999, 289: 1262-70.
23. Williams, D.L. Jr., Murphy. K.L., Nolan, N.A. et al. Pharmacology of L-754,142, a highly potent, orally active, nonpeptidyl endothelin antagonist. J Pharmacol Exp Ther 1995, 275: 1518-26.
24. Ohlstein, E.H., Nambi, P., Hay, D.W., Gellai, M., Brooks, D.P., Luengo, J., Xiang, J.N., Elliott, J.D. Nonpeptide endothelin receptor antagonists XI. Pharmacological characterization of SB 234551, a high-affinity and selective nonpeptide ETA receptor antagonist. J Pharmacol Exp Ther 1998, 286: 650-6.
25. Ohlstein, E.H., Nambi, P., Douglas, S.A. et al. SB 209670, a rationally designed potent nonpeptide endothelin receptor antagonist. Proc Natl Acad Sci USA 1994, 91: 8052-6.
26. Ohlstein, E.H., Nambi, P., Lago, A., Hay, D.W., Beck, G., Fong, K.L., Eddy, E.P., Smith, P., Ellens, H., Elliott, J.D. Nonpeptide endothelin receptor antagonists. VI: Pharmacological characterization of SB 217242, a potent and highly bioavailable endothelin receptor antagonist. J Pharmacol Exp Ther 1996, 276: 609-15.
27. Ohlstein, E.H., Beck, G.R. Jr., Douglas. S.A., Nambi, P., Lago, M.A., Gleason, J.G., Ruffolo, R.R. Jr., Feuerstein, G., Elliott, J.D. Nonpeptide endothelin receptor antagonists. II. Pharmacological characterization of SB 209670. J Pharmacol Exp Ther 1994, 271: 762-8.
28. Raschack, M., Gock, S., Unger, L., Hahn, A., Amberg, W., Jansen, R., Alken, P., Weber, A., Hergenroder, S. LU 302872 and its racemate (LU 224332) show balanced endothelin-A/B receptor affinity, high oral activity, and inhibit human prostate tissue contractions. J Cardiovasc Pharmacol 1998, 31 (Suppl 1.): S241-4.
29. Riechers, H., Albrecht, H.P., Amberg, W. et al. Discovery and optimization of a novel class of orally active nonpeptidic endothelin-A receptor antagonists. J Med Chem 1996, 39: 2123-8.
30. Roux, S., Breu, V., Giller, T., Neidhart. W., Ramuz, H., Coassolo, P., Clozel, J.P., Clozel, M. Ro 61-1790, a new hydrosoluble endothelin antagonist: General pharmacology and effects on experimental cerebral vasospasm. J Pharmacol Exp Ther 1997, 283: 1110-8.
31. A receptor antagonist. Jpn J Pharmacol 1997, 73(Suppl. 1): Abst P-143.
32. Masuda, Y., Sugo, T., Kikuchi, T., Kawata, A., Satoh, M., Fujisawa, Y., Itoh, Y., Wakimasu, M., Ohtaki, T Receptor binding and antagonist properties of a novel endothelin receptor antagonist, TAK-044 [cyclo[D-α-aspartyl-3-[(4-phenylpiperazin-1-yl)carbonytl-L-alanyl-L- α-aspartyl-D-2-(2-thienyl)glycyl-L-leucyl-D-tryptophyljdisodium salt], in human endothelinA and endothelinB receptors. J Pharmacol Exp Ther 1996, 279: 675-85.
33. Clozel, M., Ramuz, H., Clozel, J.P., Breu, V., Hess, P., Loffler, B.M., Coassolo, P., Roux, S. Pharmacology of tezosentan, new endothelin receptor antagonist designed for parenteral use. J Pharmacol Exp Ther 1999, 290: 840-6.